BUY PRIMOBOLAN (METHENOLONE ACETATE) — 25 MG/TAB. – 50 TABS

Primobolan (methenolone acetate) is a synthetic, orally active anabolic-androgenic steroid and DHT derivative.

According to the supplied information, methenolone acetate can be used in the treatment of bone marrow disease and anaemia. The source also describes methenolone acetate as having lower hepatic toxicity compared with its 17-alpha-alkylated analogues and states that it does not aromatise to oestrogen.

PRIMOBOLAN Clinical Pharmacology

Anabolic steroids are synthetic derivatives of testosterone. Their clinical effects and adverse reactions demonstrate androgenic properties, and complete separation of anabolic and androgenic effects has not been achieved.

Exogenous anabolic androgens can inhibit endogenous testosterone release through suppression of pituitary luteinising hormone (LH). At larger doses, spermatogenesis may be suppressed through feedback inhibition of follicle-stimulating hormone (FSH).

The supplied information states that methenolone acts on the androgen receptor and stimulates anabolic activity through increased nitrogen retention and protein synthesis in muscle tissue.

A single-dose pharmacokinetic study cited in the supplied information reported a mean elimination half-life of approximately 6 days.

Indications

The supplied product information lists Primobolan as an alternate or adjunctive therapy for:

• Promotion of weight gain.
• Muscular atrophy associated with extensive surgery.
• Muscular atrophy associated with infections.
• Muscular atrophy associated with long-term hospitalisation.
• Muscular atrophy associated with severe trauma.
• Compensation for protein catabolism resulting from corticosteroid therapy.

Dosage and Administration

The supplied information states:

• Adult males: 50–75 mg per day.
• Adult females: 25–50 mg per day.
• Duration: 4–6 weeks.
• The source states that adult males should not exceed 100–150 mg per day.

Dosage and treatment duration should be determined by an appropriately qualified healthcare professional based on the individual clinical circumstances.

Adverse Reactions

Reported adverse reactions in the supplied information include:

Male: Gynaecomastia, increased frequency of erections, azoospermia, priapism, oligospermia, prostatic hypertrophy and increased risk of prostate carcinoma.

Skin and Appendages: Hirsutism, pattern baldness and acne.

Fluid and Electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium and inorganic phosphates.

Gastrointestinal and Hepatic: Nausea, cholestatic jaundice and alterations in liver function tests. Rare reactions include hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas and cholestatic hepatitis.

Hematologic: Suppression of clotting factors II, V, VII and X, with bleeding possible in patients receiving anticoagulant therapy.

Nervous System: Increased or decreased libido, headache, anxiety, depression and generalised paraesthesia.

Metabolic: Reduced glucose tolerance and inhibition of gonadotrophin secretion.

Other: Serum lipid changes, hypercalcaemia, hypertension, oedema and potentiation of sleep apnoea.

Contraindications

The supplied information lists contraindications including:

• Diagnosed or suspected carcinoma of the prostate, breast or testis.
• Diagnosed or suspected female breast carcinoma with hypercalcaemia.
• Pregnancy or the possibility of pregnancy because of the potential for masculinisation of the fetus.
• Nephrosis or the nephrotic phase of nephritis.
• Hypercalcaemia.
• Hypersensitivity to the product or any of its ingredients.
• Pre-existing cardiac, renal and/or hepatic disease.

The source advises discontinuation upon signs of jaundice or hepatotoxicity.

Precautions

The supplied information recommends caution because androgens may alter serum cholesterol concentrations, particularly in patients with a history of myocardial infarction or coronary artery disease.

Patients receiving oral anticoagulant therapy require close monitoring, particularly when androgen treatment is started or stopped.

In patients with diabetes mellitus, androgens may alter the metabolism of oral hypoglycaemic medicines or insulin sensitivity, potentially requiring adjustment of antidiabetic treatment.

Patient Monitoring

The supplied product information lists monitoring of:

• Serum cholesterol
• HDL
• LDL
• Triglycerides
• Haemoglobin and haematocrit
• Hepatic function tests, including AST/ALT
• Prostate-specific antigen (PSA)
• Total, free and bioavailable testosterone
• Dihydrotestosterone (DHT)
• Oestradiol

For male patients over 40, the supplied information recommends prostate evaluation, including digital rectal examination and PSA assessment before androgen use, with periodic prostate evaluations during treatment.

Drug Interactions

The supplied information identifies potential interactions with:

• Oral hypoglycaemic agents: Anabolic steroids may inhibit their metabolism and may require dosage adjustment.
• Anticoagulants: Anabolic steroids may increase sensitivity to oral anticoagulants. Patients receiving anticoagulant therapy should be carefully monitored, particularly when starting or stopping anabolic steroid therapy.

Presentation

Primobolan (Methenolone Acetate) is supplied as 25 mg uncoated tablets, with 50 tablets in the bottle.

Storage